Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 136

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 136
---
 same period in 2024, this represented an increase of $229,551, or 48%,
with the details set forth in the table below:

    Six
    Months Ended June 30, 2025 and 2024

    2025

    2024

    $
    Change

    %
    Change

    Consultant
     
    $
    195,663

    $
    137,390

    $
    58,273

    42
    %

    Lab Gas

    1,062

    1,452

    (390
    )

    (27
    )%

    Lab Cell Storage

    31,223

    51,398

    (20,175
    )

    (39
    )%

    Chemistry Manufacturing
    and Controls (“CMC”)

    470,799

    169,617

    301,182

    178
    %

    IP Services

    10,365

    119,704

    (109,339
    )

    (91
    )%

    Total
     
    $
    709,112

    $
    479,561

    $
    229,551

    48
    %

The
Company incurred increased research and development expenses for the six months ended June 30, 2025, as compared to the corresponding
period in 2024 primarily as a result of an increase in CMC.

Professional
Fees

We
incurred professional expenses for the six months ended June 30, 2025 and 2024 of $2,155,155 and $1,221,072, respectively. For
the six months ended June 30, 2025, compared to the same period in 2024, this represented an increase of $934,083, or 76%, as
a result of increased legal and accounting fees in 2024 due to the Company’s merger.

Other
Expense

We
incurred other expense for the six months ended June 30, 2025 of $352,150 as compared to other expense for the six months ended
June 30, 2024 of $635,881. For the six months ended June 30, 2025, compared to the same period in 2024, this represented a decrease
of $283,731 or 45%. The other expense for the six months ended June